These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28094061)

  • 1. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.
    Larsabal M; Marti A; Jacquemin C; Rambert J; Thiolat D; Dousset L; Taieb A; Dutriaux C; Prey S; Boniface K; Seneschal J
    J Am Acad Dermatol; 2017 May; 76(5):863-870. PubMed ID: 28094061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
    Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
    Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies.
    Dousset L; Boniface K; Seneschal J
    G Ital Dermatol Venereol; 2019 Aug; 154(4):435-443. PubMed ID: 30650959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.
    Strassner JP; Rashighi M; Ahmed Refat M; Richmond JM; Harris JE
    J Am Acad Dermatol; 2017 May; 76(5):847-855.e5. PubMed ID: 28259440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus.
    Yang Y; Li S; Zhu G; Zhang Q; Wang G; Gao T; Li C; Wang L; Jian Z
    J Dermatol Sci; 2017 Jul; 87(1):50-59. PubMed ID: 28385330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.
    Rashighi M; Agarwal P; Richmond JM; Harris TH; Dresser K; Su MW; Zhou Y; Deng A; Hunter CA; Luster AD; Harris JE
    Sci Transl Med; 2014 Feb; 6(223):223ra23. PubMed ID: 24523323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
    Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
    J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of chemokines and the corresponding receptors in vitiligo: A pilot study.
    Yang L; Yang S; Lei J; Hu W; Chen R; Lin F; Xu AE
    J Dermatol; 2018 Jan; 45(1):31-38. PubMed ID: 29115683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.
    Wang XX; Wang QQ; Wu JQ; Jiang M; Chen L; Zhang CF; Xiang LH
    Br J Dermatol; 2016 Jun; 174(6):1318-26. PubMed ID: 26801009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

  • 14. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo.
    Sosa JJ; Currimbhoy SD; Ukoha U; Sirignano S; O'Leary R; Vandergriff T; Hynan LS; Pandya AG
    J Am Acad Dermatol; 2015 Aug; 73(2):272-5. PubMed ID: 26054430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
    Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
    Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
    Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML
    JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
    Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
    Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.